The global sickle cell disease drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Sickle cell anaemia is one of several disorders commonly known as sickle cell disease. Sickle cell anaemia is an inherited red blood cell disorder in which there are insufficient healthy red blood cells to transport oxygen throughout the body. Normally, red blood cells are flexible and move easily through blood vessels. The major factor contributing to the growth of the market is the increasing prevalence of the sickle disease (SCD) across the globe.
According to the Center for Disease Control and Prevention (CDC), in 2020, SCD affects approximately 100,000 Americans and occurs among about 1 out of every 365 Black or African-American births. Additionally, SCD occurs among 1 out of every 16,300 Hispanic-American births and about 1 in 13 Black or African-American babies is born with sickle cell trait (SCT). Hence, the increasing prevalence of SDC is driving the growth of the global sickle cell disease drug market.
To Request a Sample of our Report on Sickle Cell Disease Drug Market: https://www.omrglobal.com/request-sample/sickle-cell-disease-drug-market
Some major players operating in the market include Novartis International AG, Global Blood Therapeutics Inc., and Bluebird bio, Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in November 2019, Novartis declared the approval of Adakveo (crizanlizumab), previously known as SEG101 from the US Food and Drug Administration (FDA). This drug is used to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult and pediatric patients aged 16 years and older with sickle cell disease.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
Segment Covered-
- By Drug Type
- By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Novartis International AG, Global Blood Therapeutics Inc., and Bluebird bio, Inc., among others.
(Get 15% Discount on Buying this Report)
A full Report of Sickle Cell Disease Drug Market is Available @ https://www.omrglobal.com/industry-reports/sickle-cell-disease-drug-market
Global Sickle Cell Disease Drug Market Report by Segment
By Drug Type
- Hydroxyurea
- Antibiotics
- Pain-Relieving Medications
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Sickle Cell Disease Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
